Enhanced	0	8	O
IGF	9	12	B-Gene_or_gene_product
-	12	13	I-Gene_or_gene_product
1	13	14	I-Gene_or_gene_product
expression	15	25	O
improves	26	34	O
smooth	35	41	B-Cell
muscle	42	48	I-Cell
cell	49	53	I-Cell
engraftment	54	65	O
after	66	71	O
cell	72	76	B-Cell
transplantation	77	92	O
.	92	93	O

The	95	98	O
functional	99	109	O
benefit	110	117	O
of	118	120	O
cell	121	125	B-Cell
transplantation	126	141	O
after	142	147	O
a	148	149	O
myocardial	150	160	O
infarction	161	171	O
is	172	174	O
diminished	175	185	O
by	186	188	O
early	189	194	O
cell	195	199	B-Cell
losses	200	206	O
.	206	207	O

IGF	208	211	B-Gene_or_gene_product
-	211	212	I-Gene_or_gene_product
1	212	213	I-Gene_or_gene_product
enhances	214	222	O
cell	223	227	B-Cell
proliferation	228	241	O
and	242	245	O
survival	246	254	O
.	254	255	O

We	256	258	O
hypothesized	259	271	O
that	272	276	O
IGF	277	280	B-Gene_or_gene_product
-	280	281	I-Gene_or_gene_product
1	281	282	I-Gene_or_gene_product
-	282	283	O
transfected	283	294	O
smooth	295	301	B-Cell
muscle	302	308	I-Cell
cells	309	314	I-Cell
(	315	316	O
SMCs	316	320	B-Cell
)	320	321	O
would	322	327	O
enhance	328	335	O
cell	336	340	B-Cell
survival	341	349	O
and	350	353	O
improve	354	361	O
engraftment	362	373	O
after	374	379	O
cell	380	384	B-Cell
transplantation	385	400	O
.	400	401	O

The	402	405	O
IGF	406	409	B-Gene_or_gene_product
-	409	410	I-Gene_or_gene_product
1	410	411	I-Gene_or_gene_product
gene	412	416	O
was	417	420	O
transfected	421	432	O
into	433	437	O
male	438	442	O
SMCs	443	447	B-Cell
and	448	451	O
compared	452	460	O
with	461	465	O
SMCs	466	470	B-Cell
transfected	471	482	O
with	483	487	O
a	488	489	O
plasmid	490	497	O
vector	498	504	O
(	505	506	O
vector	506	512	O
control	513	520	O
)	520	521	O
and	522	525	O
nontransfected	526	540	O
SMCs	541	545	B-Cell
(	546	547	O
cell	547	551	B-Cell
control	552	559	O
)	559	560	O
.	560	561	O

IGF	562	565	B-Gene_or_gene_product
-	565	566	I-Gene_or_gene_product
1	566	567	I-Gene_or_gene_product
mRNA	568	572	O
(	573	574	O
n	574	575	O
=	575	576	O
10	576	578	O
/	578	579	O
group	579	584	O
)	584	585	O
and	586	589	O
protein	590	597	O
levels	598	604	O
(	605	606	O
n	606	607	O
=	607	608	O
6	608	609	O
/	609	610	O
group	610	615	O
)	615	616	O
were	617	621	O
higher	622	628	O
(	629	630	O
P	630	631	O
less	633	637	O
than	638	642	O
0	643	644	O
.	644	645	O
05	645	647	O
for	648	651	O
all	652	655	O
groups	656	662	O
)	662	663	O
at	664	666	O
3	667	668	O
,	668	669	O
7	670	671	O
,	671	672	O
and	673	676	O
14	677	679	O
days	680	684	O
compared	685	693	O
with	694	698	O
controls	699	707	O
.	707	708	O

VEGF	709	713	B-Gene_or_gene_product
was	714	717	O
also	718	722	O
increased	723	732	O
in	733	735	O
parallel	736	744	O
to	745	747	O
enhanced	748	756	O
IGF	757	760	B-Gene_or_gene_product
-	760	761	I-Gene_or_gene_product
1	761	762	I-Gene_or_gene_product
expression	763	773	O
.	773	774	O

IGF	775	778	B-Gene_or_gene_product
-	778	779	I-Gene_or_gene_product
1	779	780	I-Gene_or_gene_product
-	780	781	O
transfected	781	792	O
cells	793	798	B-Cell
demonstrated	799	811	O
greater	812	819	O
cell	820	824	B-Cell
proliferation	825	838	O
,	838	839	O
stimulated	840	850	O
angiogenesis	851	863	O
,	863	864	O
and	865	868	O
decreased	869	878	O
caspase	879	886	B-Gene_or_gene_product
-	886	887	I-Gene_or_gene_product
3	887	888	I-Gene_or_gene_product
activity	889	897	O
after	898	903	O
simulated	904	913	O
ischemia	914	922	O
and	923	926	O
reperfusion	927	938	O
(	939	940	O
P	940	941	O
less	943	947	O
than	948	952	O
0	953	954	O
.	954	955	O
05	955	957	O
for	958	961	O
all	962	965	O
groups	966	972	O
compared	973	981	O
with	982	986	O
vector	987	993	O
or	994	996	O
cell	997	1001	B-Cell
controls	1002	1010	O
)	1010	1011	O
.	1011	1012	O

A	1013	1014	O
uniform	1015	1022	O
left	1023	1027	O
ventricular	1028	1039	O
injury	1040	1046	O
was	1047	1050	O
produced	1051	1059	O
in	1060	1062	O
female	1063	1069	O
rats	1070	1074	B-Organism
using	1075	1080	O
a	1081	1082	O
cryoprobe	1083	1092	O
.	1092	1093	O

Three	1094	1099	O
weeks	1100	1105	O
later	1106	1111	O
,	1111	1112	O
2	1113	1114	O
x	1115	1116	O
10	1117	1119	O
(	1119	1120	O
6	1120	1121	O
)	1121	1122	O
cells	1123	1128	B-Cell
from	1129	1133	O
three	1134	1139	O
groups	1140	1146	O
were	1147	1151	O
implanted	1152	1161	O
into	1162	1166	O
the	1167	1170	O
scar	1171	1175	O
.	1175	1176	O

One	1177	1180	O
week	1181	1185	O
later	1186	1191	O
,	1191	1192	O
IGF	1193	1196	B-Gene_or_gene_product
-	1196	1197	I-Gene_or_gene_product
1	1197	1198	I-Gene_or_gene_product
-	1198	1199	O
transfected	1199	1210	O
SMCs	1211	1215	B-Cell
had	1216	1219	O
increased	1220	1229	O
myocardial	1230	1240	O
IGF	1241	1244	B-Gene_or_gene_product
-	1244	1245	I-Gene_or_gene_product
1	1245	1246	I-Gene_or_gene_product
and	1247	1250	O
VEGF	1251	1255	B-Gene_or_gene_product
levels	1256	1262	O
,	1262	1263	O
increased	1264	1273	O
Bcl2	1274	1278	B-Gene_or_gene_product
expression	1279	1289	O
,	1289	1290	O
limited	1291	1298	O
cell	1299	1303	B-Cell
apoptosis	1304	1313	O
,	1313	1314	O
and	1315	1318	O
enhanced	1319	1327	O
vessel	1328	1334	B-Multi-tissue_structure
formation	1335	1344	O
in	1345	1347	O
the	1348	1351	O
myocardial	1352	1362	O
scar	1363	1367	O
compared	1368	1376	O
with	1377	1381	O
the	1382	1385	O
two	1386	1389	O
control	1390	1397	O
groups	1398	1404	O
(	1405	1406	O
P	1406	1407	O
less	1409	1413	O
than	1414	1418	O
0	1419	1420	O
.	1420	1421	O
05	1421	1423	O
for	1424	1427	O
all	1428	1431	O
groups	1432	1438	O
)	1438	1439	O
.	1439	1440	O

The	1441	1444	O
proportion	1445	1455	O
of	1456	1458	O
SMCs	1459	1463	B-Cell
surviving	1464	1473	O
in	1474	1476	O
the	1477	1480	O
implanted	1481	1490	O
region	1491	1497	O
was	1498	1501	O
greater	1502	1509	O
(	1510	1511	O
P	1511	1512	O
less	1514	1518	O
than	1519	1523	O
0	1524	1525	O
.	1525	1526	O
05	1526	1528	O
)	1528	1529	O
in	1530	1532	O
the	1533	1536	O
IGF	1537	1540	B-Gene_or_gene_product
-	1540	1541	I-Gene_or_gene_product
1	1541	1542	I-Gene_or_gene_product
-	1542	1543	O
transfected	1543	1554	O
group	1555	1560	O
than	1561	1565	O
in	1566	1568	O
the	1569	1572	O
vector	1573	1579	O
or	1580	1582	O
cell	1583	1587	B-Cell
controls	1588	1596	O
.	1596	1597	O

Gene	1598	1602	O
enhancement	1603	1614	O
with	1615	1619	O
IGF	1620	1623	B-Gene_or_gene_product
-	1623	1624	I-Gene_or_gene_product
1	1624	1625	I-Gene_or_gene_product
improved	1626	1634	O
donor	1635	1640	B-Cell
cell	1641	1645	I-Cell
proliferation	1646	1659	O
,	1659	1660	O
survival	1661	1669	O
,	1669	1670	O
and	1671	1674	O
engraftment	1675	1686	O
after	1687	1692	O
cell	1693	1697	B-Cell
transplantation	1698	1713	O
,	1713	1714	O
perhaps	1715	1722	O
mediated	1723	1731	O
by	1732	1734	O
enhanced	1735	1743	O
angiogenesis	1744	1756	O
and	1757	1760	O
reduced	1761	1768	O
apoptosis	1769	1778	O
.	1778	1779	O

